Table 1.
Clinical and pathologic characteristics of study population
| Characteristic | Number | % |
|---|---|---|
| n=202 | ||
| Age | ||
| <50 | 62 | 32.1 |
| >50 | 131 | 67.8 |
| Estrogen Receptor | ||
| Positive | 110 | 57 |
| Negative | 83 | 43 |
| Progesterone Receptor | ||
| Positive | 92 | 47.7 |
| Negative | 101 | 52.3 |
| HER2 Status | ||
| Positive | 27 | 14 |
| Negative | 166 | 86 |
| Subtype* | ||
| Luminal A | 84 | 43.5 |
| Luminal B | 27 | 14 |
| Her2 | 17 | 8.8 |
| Triple Negative | 65 | 33.7 |
| Pathologic Stage Group | ||
| 1 | 60 | 31.1 |
| 2 | 80 | 41.5 |
| 3 | 40 | 20.7 |
| 4 | 12 | 6.2 |
| Unknown | 1 | 0.5 |
| Grade | ||
| I | 9 | 4.6 |
| II | 54 | 28 |
| III | 130 | 67.4 |
| Recurrence | ||
| None | 147 | 76.2 |
| Loco-regional | 8 | 4.1 |
| Distant | 21 | 10.9 |
| Never Disease free | 8 | 4.1 |
| Unknown | 9 | 4.7 |
+N=202
ER, estrogen receptor; PR, progesterone receptor.
*
Luminal A: ER+ or PR+, HER2−; luminal B: ER+ or PR+, HER2+; triple-negative: ER−, PR−, HER2−; Her2+: ER−, PR−, HER2+